Benzinga | Jan 21, 2022 07:32AM EST

UBS Initiates Coverage On Moderna with Neutral Rating, Announces Price Target of $221

UBS analyst Eliana Merle initiates coverage on Moderna (NASDAQ:MRNA) with a Neutral rating and announces Price Target of $221.